UA78279C2 - Orally dispersible pharmaceutical perindopril composition - Google Patents

Orally dispersible pharmaceutical perindopril composition Download PDF

Info

Publication number: UA78279C2
Authority: UA; Ukraine
Prior art keywords: perindopril; pharmaceutically acceptable; pharmaceutical composition; differs; tablet
Prior art date: 2002-01-23

Application number

UA20040806966A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-23

Filing date

2003-01-22

Publication date

2007-03-15

2003-01-22 Application filed by Servier Lab filed Critical Servier Lab

2007-03-15 Publication of UA78279C2 publication Critical patent/UA78279C2/uk

Links

229960002582 perindopril Drugs 0.000 title claims abstract description 25
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims abstract description 24
239000000203 mixture Substances 0.000 title claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
239000008187 granular material Substances 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 11
239000007787 solid Substances 0.000 claims abstract description 9
229920002472 Starch Polymers 0.000 claims abstract description 8
239000008107 starch Substances 0.000 claims abstract description 8
235000019698 starch Nutrition 0.000 claims abstract description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 7
239000008101 lactose Substances 0.000 claims abstract description 7
238000004519 manufacturing process Methods 0.000 claims description 8
238000007906 compression Methods 0.000 claims description 4
230000006835 compression Effects 0.000 claims description 4
235000003599 food sweetener Nutrition 0.000 claims description 4
239000003765 sweetening agent Substances 0.000 claims description 4
206010019280 Heart failures Diseases 0.000 claims description 3
208000037849 arterial hypertension Diseases 0.000 claims description 3
239000000314 lubricant Substances 0.000 claims description 3
239000008247 solid mixture Substances 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
210000000214 mouth Anatomy 0.000 description 16
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
239000002552 dosage form Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
239000008119 colloidal silica Substances 0.000 description 8
239000000945 filler Substances 0.000 description 8
IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 7
238000005303 weighing Methods 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 6
239000007884 disintegrant Substances 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 3
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
108010011485 Aspartame Proteins 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
239000000619 acesulfame-K Substances 0.000 description 2
239000000605 aspartame Substances 0.000 description 2
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
229960003438 aspartame Drugs 0.000 description 2
235000010357 aspartame Nutrition 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
229940045902 sodium stearyl fumarate Drugs 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
102000005862 Angiotensin II Human genes 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
102000003729 Neprilysin Human genes 0.000 description 1
108090000028 Neprilysin Proteins 0.000 description 1
MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000035622 drinking Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
229940071138 stearyl fumarate Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Zoology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA20040806966A 2002-01-23 2003-01-22 Orally dispersible pharmaceutical perindopril composition UA78279C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0200790A FR2834893B1 (fr)	2002-01-23	2002-01-23	Composition pharmaceutique orodispersible de perindopril
PCT/FR2003/000200 WO2003061691A1 (fr)	2002-01-23	2003-01-22	Composition pharmaceutique orodispersible de perindopril

Publications (1)

Publication Number	Publication Date
UA78279C2 true UA78279C2 (en)	2007-03-15

Family

ID=27589554

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040806966A UA78279C2 (en)	2002-01-23	2003-01-22	Orally dispersible pharmaceutical perindopril composition

Country Status (26)

Country	Link
US (3)	US20050106237A1 (pl)
EP (1)	EP1467750B1 (pl)
JP (1)	JP4090997B2 (pl)
KR (1)	KR100588224B1 (pl)
CN (1)	CN1658898B (pl)
AR (1)	AR038305A1 (pl)
AT (1)	ATE332690T1 (pl)
AU (1)	AU2003215708B2 (pl)
BR (1)	BRPI0307048B1 (pl)
CA (1)	CA2473205C (pl)
CY (1)	CY1105655T1 (pl)
DE (1)	DE60306747T2 (pl)
DK (1)	DK1467750T3 (pl)
EA (1)	EA007181B1 (pl)
ES (1)	ES2268372T3 (pl)
FR (1)	FR2834893B1 (pl)
GE (1)	GEP20063821B (pl)
MA (1)	MA27099A1 (pl)
MX (1)	MXPA04007195A (pl)
NO (1)	NO333723B1 (pl)
NZ (1)	NZ533821A (pl)
PL (1)	PL205473B1 (pl)
PT (1)	PT1467750E (pl)
UA (1)	UA78279C2 (pl)
WO (1)	WO2003061691A1 (pl)
ZA (1)	ZA200405009B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1734931A2 (en) *	2004-03-24	2006-12-27	Actavis Group	Formulations of ramipril
DE102004019845A1 (de) *	2004-03-29	2005-10-20	Krka Tovarna Zdravil D D	Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung
SK50252005A3 (sk) *	2005-03-22	2006-10-05	Vúlm, A.S.	Farmaceutický prípravok obsahujúci perindopril erbumín, spôsob jeho prípravy a stabilizácie
GB0518129D0 (en) *	2005-09-06	2005-10-12	Arrow Int Ltd	Ramipril formulation
GB2431579A (en) *	2005-10-28	2007-05-02	Arrow Int Ltd	Ramipril formulations
US20070098782A1 (en) *	2005-10-28	2007-05-03	Selamine Limited	Ramipril Formulation
GB0624090D0 (en) *	2006-12-01	2007-01-10	Selamine Ltd	Ramipril amine salts
GB0624087D0 (en) *	2006-12-01	2007-01-10	Selamine Ltd	Ramipril combination salt
GB0624084D0 (en) *	2006-12-01	2007-01-10	Selamine Ltd	Ramipril amino acid salts
ES2716990T5 (es)	2013-12-23	2023-03-24	Dr Falk Pharma Gmbh	Formulación farmacéutica optimizada para el tratamiento de cambios inflamatorios del esófago
WO2016174664A1 (en) *	2015-04-29	2016-11-03	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3506276C1 (de) *	1985-02-22	1986-04-24	Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring	Direkttablettiermittel
JP3122141B2 (ja) *	1994-01-31	2001-01-09	山之内製薬株式会社	口腔内溶解型圧縮成型物及びその製造法
CA2322315C (en) *	1998-03-06	2008-09-16	Eurand International S.P.A.	Fast disintegrating tablets
US6740339B1 (en) *	1999-06-18	2004-05-25	Takeda Chemical Industries, Ltd.	Quickly disintegrating solid preparations
FR2811318B1 (fr) *	2000-07-06	2002-08-23	Adir	Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
EP1175899B1 (fr) *	2000-07-27	2007-08-29	Roquette FrÀ¨res	Granules à base d'amidon et de lactose
US6651768B2 (en) *	2000-11-06	2003-11-25	Bombardier Inc.	Snowmobile engine mount
FR2834889B1 (fr) *	2002-01-18	2004-04-02	Roquette Freres	Forme pharmaceutique solide orodispersible

2002
- 2002-01-23 FR FR0200790A patent/FR2834893B1/fr not_active Expired - Fee Related
2003
- 2003-01-22 DK DK03731736T patent/DK1467750T3/da active
- 2003-01-22 PT PT03731736T patent/PT1467750E/pt unknown
- 2003-01-22 BR BRPI0307048-4A patent/BRPI0307048B1/pt not_active IP Right Cessation
- 2003-01-22 MX MXPA04007195A patent/MXPA04007195A/es active IP Right Grant
- 2003-01-22 UA UA20040806966A patent/UA78279C2/uk unknown
- 2003-01-22 PL PL370162A patent/PL205473B1/pl unknown
- 2003-01-22 JP JP2003561634A patent/JP4090997B2/ja not_active Expired - Fee Related
- 2003-01-22 DE DE60306747T patent/DE60306747T2/de not_active Expired - Lifetime
- 2003-01-22 KR KR1020047011349A patent/KR100588224B1/ko not_active Expired - Fee Related
- 2003-01-22 GE GE5628A patent/GEP20063821B/en unknown
- 2003-01-22 EP EP03731736A patent/EP1467750B1/fr not_active Expired - Lifetime
- 2003-01-22 CN CN038025191A patent/CN1658898B/zh not_active Expired - Fee Related
- 2003-01-22 WO PCT/FR2003/000200 patent/WO2003061691A1/fr not_active Ceased
- 2003-01-22 ES ES03731736T patent/ES2268372T3/es not_active Expired - Lifetime
- 2003-01-22 US US10/502,479 patent/US20050106237A1/en not_active Abandoned
- 2003-01-22 EA EA200400884A patent/EA007181B1/ru not_active IP Right Cessation
- 2003-01-22 AU AU2003215708A patent/AU2003215708B2/en not_active Ceased
- 2003-01-22 NZ NZ533821A patent/NZ533821A/en not_active IP Right Cessation
- 2003-01-22 AT AT03731736T patent/ATE332690T1/de active
- 2003-01-22 CA CA2473205A patent/CA2473205C/fr not_active Expired - Fee Related
- 2003-01-23 AR ARP030100195A patent/AR038305A1/es not_active Application Discontinuation
2004
- 2004-06-24 ZA ZA2004/05009A patent/ZA200405009B/en unknown
- 2004-07-06 MA MA27767A patent/MA27099A1/fr unknown
- 2004-08-20 NO NO20043473A patent/NO333723B1/no not_active IP Right Cessation
2006
- 2006-10-10 CY CY20061101450T patent/CY1105655T1/el unknown
2010
- 2010-06-22 US US12/803,207 patent/US20100267799A1/en not_active Abandoned
2011
- 2011-12-05 US US13/311,498 patent/US20120076856A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA200400884A1 (ru)	2004-12-30
US20050106237A1 (en)	2005-05-19
EA007181B1 (ru)	2006-08-25
BR0307048A (pt)	2004-10-26
ATE332690T1 (de)	2006-08-15
MA27099A1 (fr)	2004-12-20
KR100588224B1 (ko)	2006-06-12
DK1467750T3 (da)	2006-11-13
KR20040078130A (ko)	2004-09-08
AU2003215708B8 (en)	2003-09-02
ES2268372T3 (es)	2007-03-16
AU2003215708B2 (en)	2007-07-19
PL205473B1 (pl)	2010-04-30
CN1658898A (zh)	2005-08-24
NO333723B1 (no)	2013-09-02
DE60306747D1 (de)	2006-08-24
AR038305A1 (es)	2005-01-12
US20120076856A1 (en)	2012-03-29
PT1467750E (pt)	2006-11-30
HK1076743A1 (en)	2006-01-27
CA2473205C (fr)	2010-05-18
JP2005523256A (ja)	2005-08-04
MXPA04007195A (es)	2004-10-29
ZA200405009B (en)	2005-08-31
EP1467750A1 (fr)	2004-10-20
NZ533821A (en)	2005-08-26
EP1467750B1 (fr)	2006-07-12
BRPI0307048B1 (pt)	2015-06-30
WO2003061691A1 (fr)	2003-07-31
FR2834893A1 (fr)	2003-07-25
GEP20063821B (en)	2006-05-10
US20100267799A1 (en)	2010-10-21
FR2834893B1 (fr)	2004-02-27
NO20043473L (no)	2004-08-20
DE60306747T2 (de)	2007-08-02
PL370162A1 (pl)	2005-05-16
CN1658898B (zh)	2012-10-03
CY1105655T1 (el)	2010-12-22
JP4090997B2 (ja)	2008-05-28
CA2473205A1 (fr)	2003-07-31
AU2003215708B9 (en)	2003-09-02

Publication	Publication Date	Title
US20100267799A1 (en)	2010-10-21	Orodispersible pharmaceutical composition of perindopril
ES2393640T3 (es)	2012-12-26	Comprimidos bucodisgregables
US20100267693A1 (en)	2010-10-21	Orodispersible pharmaceutical composition of ivabradine
JP2008285434A (ja)	2008-11-27	口腔内速崩壊錠
JP2010241760A (ja)	2010-10-28	不快な味の軽減された口腔内速崩壊錠及びその製造方法
AU2004258713B2 (en)	2007-07-12	Orodispersible pharmaceutical composition of an antithrombotic compound
JPWO2003075919A1 (ja)	2005-06-30	塩酸ピルジカイニド含有錠剤（乾式）
JP2006206465A (ja)	2006-08-10	持続性口腔内溶解用固形製剤
UA78277C2 (en)	2007-03-15	Orally dispersible pharmaceutical piribedil composition
HK1094152B (en)	2010-03-12	Orodispersible pharmaceutical composition of an antithrombotic compound
HK1076743B (en)	2013-05-24	Orodispersible pharmaceutical composition comprising perindopril